CRISPR gene-drive technology: A new weapon against antibiotic resistance
Antibiotic resistance (AR) has become a global health crisis, with an estimated 10 million deaths worldwide by 2050. As bacteria evolve new ways to evade drug treatments, a growing number of "superbugs" have emerged, posing a significant threat to public health. Scientists are now turning to cutting-edge technologies to combat this pressing issue.
The University of California San Diego has developed a novel approach to tackle antibiotic resistance. In collaboration with the laboratories of Ethan Bier and Justin Meyer, researchers have created a CRISPR-based technology similar to gene drives. This innovative tool, called Pro-Active Genetics (Pro-AG) or pPro-MobV, aims to disable drug resistance in bacterial populations.
Bier explains, "With pPro-MobV, we've adapted gene-drive thinking from insects to bacteria, using it as a population engineering tool. This new CRISPR-based technology allows us to introduce a few cells and neutralize antibiotic resistance in a large target population."
The Pro-AG concept involves introducing a genetic cassette that inactivates antibiotic-resistant components in bacteria. This cassette targets AR genes carried on plasmids, circular DNA structures within cells. By doing so, it restores the bacteria's sensitivity to antibiotic treatments.
Bier and his team further enhanced this idea by developing a system that spreads the antibiotic CRISPR cassette components via conjugal transfer, a bacterial mating process. They demonstrated this in bacterial biofilms, which are challenging to remove and contribute to disease spread. The technology's potential extends to healthcare, environmental remediation, and microbiome engineering.
Bier highlights the significance of biofilms in combating antibiotic resistance, stating, "The biofilm context is crucial as it represents one of the most difficult bacterial growth forms to overcome in clinical settings and enclosed environments."
Additionally, the researchers explored the use of bacteriophage, or phage, as a delivery system for the active genetic system. Phage, natural bacterial competitors, can be engineered to combat antibiotic resistance by evading bacterial defenses and inserting disruptive factors. The pPro-MobV elements are envisioned to work in conjunction with these engineered phage viruses.
Justin Meyer, a professor studying bacterial and viral evolutionary adaptations, emphasizes the technology's unique ability to actively reverse the spread of antibiotic-resistant genes, offering a more proactive approach to this global health challenge.
